Principal Financial Group Inc Caribou Biosciences, Inc. Transaction History

Principal Financial Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$1.62 - $5.05 $15,885 - $49,520	-9,806 Reduced 44.53%	12,213 $20,000
Q1 2024 Apr 29, 2024	SELL	$4.82 - $8.26 $8,319 - $14,256	-1,726 Reduced 7.27%	22,019 $113,000
Q4 2023 Feb 07, 2024	SELL	$3.58 - $6.25 $5,201 - $9,081	-1,453 Reduced 5.77%	23,745 $136,000
Q3 2023 Nov 02, 2023	BUY	$4.08 - $8.14 $25,406 - $50,687	6,227 Added 32.82%	25,198 $120,000
Q2 2023 Aug 07, 2023	BUY	$4.04 - $5.47 $12,806 - $17,339	3,170 Added 20.06%	18,971 $80,000
Q1 2023 May 09, 2023	BUY	$4.3 - $7.78 $8,501 - $15,381	1,977 Added 14.3%	15,801 $83,000
Q4 2022 Feb 09, 2023	BUY	$5.57 - $11.01 $6,060 - $11,978	1,088 Added 8.54%	13,824 $86,000
Q3 2022 Nov 09, 2022	BUY	$5.34 - $12.79 $68,010 - $162,893	12,736 New	12,736 $134,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.